Evidence map›Paper›PMID 24867978›Full record

ArticleAntimicrobial agents and chemotherapy2014

In vitro and in vivo evaluation of 28DAP010, a novel diamidine for treatment of second-stage African sleeping sickness.

Tanja Wenzler, Sihyung Yang, Donald A Patrick, Olivier Braissant, Mohamed A Ismail, Richard R Tidwell, David W Boykin, Michael Zhuo Wang, Reto Brun

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Review
  3. Molecules (Basel, Switzerland) · 2023
    Article
  4. Antimicrobial agents and chemotherapy · 2018
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Tanja WenzlerMedical Parasitology & Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland University of Basel, Basel, Switzerland Tanja.Wenzler@unibas.ch.
Sihyung YangDepartment of Pharmaceutical Chemistry, School of Pharmacy, The University of Kansas, Lawrence, Kansas, USA.
Donald A PatrickDepartment of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Olivier BraissantUniversity of Basel, Basel, Switzerland Department of Urology, University Hospital of Basel, Basel, Switzerland.
Mohamed A IsmailDepartment of Chemistry, Georgia State University, Atlanta, Georgia, USA.
Richard R TidwellDepartment of Pathology and Laboratory Medicine, School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
David W BoykinDepartment of Chemistry, Georgia State University, Atlanta, Georgia, USA.
Michael Zhuo WangDepartment of Pharmaceutical Chemistry, School of Pharmacy, The University of Kansas, Lawrence, Kansas, USA.
Reto BrunMedical Parasitology & Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland University of Basel, Basel, Switzerland.
Georgia State University · USUniversity of Basel · CHUniversity of Kansas · USUniversity of North Carolina at Chapel Hill · USSwiss Tropical and Public Health Institute · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

African sleeping sickness is a neglected tropical disease transmitted by tsetse flies. New and better drugs are still needed especially for its second stage, which is fatal if untreated. 28DAP010, a dipyridylbenzene analogue of DB829, is the second simple diamidine found to cure mice with central nervous system infections by a parenteral route of administration. 28DAP010 showed efficacy similar to that of DB829 in dose-response studies in mouse models of first- and second-stage African sleeping sickness. The in vitro time to kill, determined by microcalorimetry, and the parasite clearance time in mice were shorter for 28DAP010 than for DB829. No cross-resistance was observed between 28DAP010 and pentamidine on the tested Trypanosoma brucei gambiense isolates from melarsoprol-refractory patients. 28DAP010 is the second promising preclinical candidate among the diamidines for the treatment of second-stage African sleeping sickness.

Indexed as

AmidinesAnimalsDose-Response Relationship, DrugFemaleHumansMelarsoprolMicePentamidinePyridinesStructure-Activity RelationshipTrypanocidal AgentsTrypanosoma brucei gambienseTrypanosoma brucei rhodesienseTrypanosomiasis, AfricanAmidinesCPD 0801CPD0905MelarsoprolPentamidinePyridinesTrypanocidal Agents

Identifiers

PMID24867978
PMCPMC4136055
OpenAlexW2063033944

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.